^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
CELsignia test

Company:
Celcuity
Type:
Laboratory Developed Test

Details

Evidence
The CELsignia platform identifies patients with abnormal oncogenic signaling pathways to detect new treatment options for patients. CELsignia Test measures dynamic HER2, c-Met, and PI3K-node involved signaling activity in the living tumor cells of HER2-negative breast cancer patients. CELsignia tests provide pharmaceutical companies a new type of biomarker, dysregulated signaling activity, to identify additional patients eligible for their targeted therapies.
Cancer:
Breast Cancer
Gene:
HER-2 (Human epidermal growth factor receptor 2), MET (MET proto-oncogene, receptor tyrosine kinase)